Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. The work represents a key milestone in the company's chemistry, manufacturing and controls strategy as it advances toward IND-enabling studies and planning for first-in-human clinical evaluation.
The program will focus on optimizing synthetic processes, improving yield and reproducibility and scaling production of key intermediates required for downstream manufacturing and formulation. The effort will be conducted in collaboration with Dalton Pharma Services and is intended to establish a robust, scalable manufacturing process capable of supporting continued preclinical development, regulatory readiness and future clinical supply requirements. For more details, the full press release is available at https://nnw.fm/kfFWv.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumours. More information can be found at https://oncoinnovations.com/.
This advancement is important because it moves ONC010 closer to clinical testing, potentially offering a new treatment option for solid tumours. The scale-up manufacturing process is crucial for ensuring consistent drug supply for future trials and eventual commercial use. The collaboration with Dalton Pharma Services leverages expertise in pharmaceutical manufacturing to accelerate development timelines.
As Onco-Innovations progresses, the successful development of ONC010 could address unmet medical needs in oncology. The company's focus on patented technology targeting solid tumours positions it within a competitive landscape, but the initiation of manufacturing process development marks a tangible step toward bringing the therapy to patients.
